Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)
Romain Séchaud, Karen Sinclair, Kai Grosch, Taoufik Ouatas, Dhrubajyoti Pathak
Topics & Concepts
MidostaurinConcomitantCYP3A4MedicineMyeloid leukemiaPharmacologyInternal medicinePlaceboAdverse effectNeutropeniaOncologyChemotherapyPathologyCytochrome P450MetabolismAlternative medicineAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationPharmacogenetics and Drug Metabolism